Gilead raises dividend to $0.79 per share for Q1 2025

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical firm with a market capitalization of $119.87 billion, announced today a 2.6% increase in its quarterly cash dividend. Starting in the first quarter of 2025, the dividend will be $0.79 per share of common stock, bringing the annual dividend yield to 3.23%. This dividend is set to be paid on March 28, 2025, to shareholders who are on record by March 14, 2025. According to InvestingPro data, this marks the company’s 10th consecutive year of dividend increases. The declaration of future dividends will remain at the discretion of the company’s Board of Directors.

Gilead Sciences has a history of over three decades in developing medicines aimed at treating life-threatening diseases such as HIV, viral hepatitis, COVID-19, cancer, and various inflammatory conditions. With its headquarters in Foster City, California, Gilead operates in more than 35 countries across the globe. The company maintains strong financial health, earning a "GREAT" overall score from InvestingPro’s comprehensive analysis, with particularly robust cash flow metrics.

The dividend increase reflects Gilead Sciences’ ongoing commitment to provide value to its shareholders and its confidence in the company’s financial strength. Dividend payments are a way for companies to distribute a portion of their earnings back to shareholders, and an increase in the dividend amount can be seen as a positive signal about the company’s profitability and future prospects.

Investors often view regular and increasing dividends as a sign of a company’s stable financial health and its ability to generate cash. However, it is important for investors to consider a company’s overall financial performance and not just its dividend payouts when making investment decisions.

This announcement is based on a press release statement from Gilead Sciences, Inc.

In other recent news, Gilead Sciences reported a successful fourth quarter, surpassing analyst expectations. The biopharmaceutical company announced adjusted earnings per share of $1.90 and revenue of $7.6 billion, exceeding Wall Street’s projections of $1.71 EPS and $7.16 billion in revenue. Total (EPA:TTEF) product sales saw a 7% YoY increase to $7.5 billion, fueled by a 16% growth in HIV product sales to $5.5 billion.

Additionally, Gilead provided an optimistic forecast for 2025, with expected revenue between $28.2-$28.6 billion and adjusted EPS of $7.70-$8.10, both ranges exceeding consensus analyst estimates. The company also underscored the potential launch of lenacapavir for HIV prevention in summer 2025 as a key growth driver.

These are the latest developments for Gilead Sciences, which concluded 2024 with $10 billion in cash and investments. The board also declared a quarterly dividend of $0.79 per share.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.